IDH2 and acute myeloid leukemia: We found that NPM1 and IDH2 mutations were less prevalent in R/R patients, indicating that NPM1 AML [1], and even some IDH2 types (i.e., R172) [5] could have a lower relapse rate, and that IDH2 affects older patients [16,23] that are less frequently tested at R/R episodes.